Nadège Pelletier

Dr. Nadège Pelletier holds a Ph.D. in immunology from Claude Bernard University, ENS-Lyon, in Lyon, France and a Master of Science in Genetics and Immunology from ENS-Lyon.

Dr. Pelletier brings extensive experience to Vaccitech in the areas of immunology, inflammation and infectious diseases. She joins Vaccitech from the Novartis Institutes for Biomedical Research and prior to that Roche Pharma Research & Early Development, where she served as Project Leader in the fields of autoimmunity, inflammation and infectious diseases. At Novartis, Dr. Pelletier was a discovery leader in a fast-track, multi-indication early clinical program on tolerance induction, and was responsible for maintaining accountability in building solid preclinical packages, biomarker strategies, and translational plans for disease focus and indication expansion. Prior to her role at Novartis, Dr. Pelletier was responsible for several preclinical and clinical projects in all phases of development to restore immune balance in autoimmunity and chronic infectious diseases, and was a key contributor to advancing immune modulation strategies for chronic Hepatitis B and respiratory infections.

Dr. Pelletier joined Vaccitech as CSO at the beginning of 2023, leading Vaccitech’s scientific teams in all phases of drug discovery and platform development, as well as building and overseeing the strategic technical direction of the company.